Chargement en cours...
Current status of intralesional agents in treatment of malignant melanoma
Prognosis of metastatic melanoma has undergone substantial improvement with the discovery of checkpoint inhibitors. Immunotherapies and targeted therapies have improved the median overall survival (OS) of metastatic melanoma from 6 months to more than 3 years. However, still about half of the patien...
Enregistré dans:
| Publié dans: | Ann Transl Med |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AME Publishing Company
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8267328/ https://ncbi.nlm.nih.gov/pubmed/34277838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-21-491 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|